Welcome to our dedicated page for Viewbix SEC filings (Ticker: VBIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ViewBix Inc. filings document its transition to Quantum X Labs Inc., including the certificate amendment that changed the corporate name, the Nasdaq symbol change from VBIX to QXL and related bylaw updates. The record also includes Regulation FD disclosures and other Form 8-K material-event reports.
Company filings cover registration and capital-structure matters for its common stock, private placement securities, warrants and pre-funded warrants; material agreements involving the Quantum X Labs acquisition and subsidiary dispositions; and governance disclosures involving board and committee composition. Registration materials and periodic disclosure categories also address operating results, risk factors, reporting status and security-holder rights.
Quantum X Labs Inc. appointed Yakov Baranes as co-Chief Executive Officer, effective May 18, 2026, alongside existing CEO Amihay Hadad, who will continue in a co-CEO structure. Baranes has 11 years of strategy experience across industries and government entities and has led Quantum X Labs Ltd., the company’s Israeli quantum-focused subsidiary, since March 2025.
Under a new agreement effective June 1, 2026, Baranes will receive a base salary of NIS 36,000 + VAT per month as co-CEO, plus NIS 24,000 + VAT per month for services to Quantum Israel, with eligibility for board-determined bonuses. The agreement is open-ended with a 60-day termination notice by either party, and immediate termination for cause is permitted.
In the March 2026 acquisition of Quantum Israel, Baranes, who previously held 32,647 shares (approximately 5.54%) of Quantum Israel, received 103,373 shares of common stock and pre-funded warrants to purchase 246,387 shares of Quantum X Labs common stock and may receive up to an additional 703,710 shares or pre-funded warrants upon achieving specified milestones.
Quantum X Labs Inc. appointed Yakov Baranes as co-Chief Executive Officer, effective May 18, 2026, alongside existing CEO Amihay Hadad, who will continue in a co-CEO structure. Baranes has 11 years of strategy experience across industries and government entities and has led Quantum X Labs Ltd., the company’s Israeli quantum-focused subsidiary, since March 2025.
Under a new agreement effective June 1, 2026, Baranes will receive a base salary of NIS 36,000 + VAT per month as co-CEO, plus NIS 24,000 + VAT per month for services to Quantum Israel, with eligibility for board-determined bonuses. The agreement is open-ended with a 60-day termination notice by either party, and immediate termination for cause is permitted.
In the March 2026 acquisition of Quantum Israel, Baranes, who previously held 32,647 shares (approximately 5.54%) of Quantum Israel, received 103,373 shares of common stock and pre-funded warrants to purchase 246,387 shares of Quantum X Labs common stock and may receive up to an additional 703,710 shares or pre-funded warrants upon achieving specified milestones.
Quantum X Labs Inc. Amendment No. 1 to a Schedule 13G/A reports that L.I.A. Pure Capital Ltd. beneficially owns 1,332,366 shares of common stock. The filing states this represents 9.99% of the class based on 13,336,392 shares outstanding as of the date hereof. The filing also notes that 7,079,877 Shares may be acquired within 60 days through exercise of warrants, subject to a blocker provision that limits exercise to prevent beneficial ownership above 4.99%. The amendment is signed by Kfir Silberman, Chief Executive Officer on 05/15/2026.
Quantum X Labs Inc. Amendment No. 1 to a Schedule 13G/A reports that L.I.A. Pure Capital Ltd. beneficially owns 1,332,366 shares of common stock. The filing states this represents 9.99% of the class based on 13,336,392 shares outstanding as of the date hereof. The filing also notes that 7,079,877 Shares may be acquired within 60 days through exercise of warrants, subject to a blocker provision that limits exercise to prevent beneficial ownership above 4.99%. The amendment is signed by Kfir Silberman, Chief Executive Officer on 05/15/2026.
Capitalink Ltd. amended its Schedule 13G to report beneficial ownership in X Labs Inc. The filing states Capitalink beneficially owns 667,034 shares, representing 4.99% of X Labs' 13,336,392 shares outstanding used for the calculation. The filing counts 38,000 additional shares issuable upon exercise of warrants within 60 days and notes a 44,283-share warrant subject to a blocker provision.
Capitalink Ltd. amended its Schedule 13G to report beneficial ownership in X Labs Inc. The filing states Capitalink beneficially owns 667,034 shares, representing 4.99% of X Labs' 13,336,392 shares outstanding used for the calculation. The filing counts 38,000 additional shares issuable upon exercise of warrants within 60 days and notes a 44,283-share warrant subject to a blocker provision.
X Labs Inc. filed an amendment to a Schedule 13G/A reporting beneficial ownership of 1,179,230 shares of Common Stock, representing 8.65% of the class. The filing states this percentage was calculated based on 13,336,392 shares outstanding as of the date hereof.
The filing explains the 1,179,230 figure consists of 879,230 Shares plus 300,000 Shares issuable upon conversion of a convertible loan. It also discloses additional potential shares tied to warrants: 44,283 Shares exercisable within 60 days and 300,000 Shares issuable upon conversion-related warrants, each subject to a blocker provision limiting exercises above 4.99%.
X Labs Inc. filed an amendment to a Schedule 13G/A reporting beneficial ownership of 1,179,230 shares of Common Stock, representing 8.65% of the class. The filing states this percentage was calculated based on 13,336,392 shares outstanding as of the date hereof.
The filing explains the 1,179,230 figure consists of 879,230 Shares plus 300,000 Shares issuable upon conversion of a convertible loan. It also discloses additional potential shares tied to warrants: 44,283 Shares exercisable within 60 days and 300,000 Shares issuable upon conversion-related warrants, each subject to a blocker provision limiting exercises above 4.99%.
Quantum X Labs Inc. reported unaudited results for the quarter ended March 31, 2026, showing a small business focused on quantum technology and digital advertising that is still losing money. Revenue from continuing operations was $353 thousand, down from $529 thousand a year earlier, while net loss attributable to shareholders narrowed to $605 thousand from $3.7 million. Total assets rose to $27.7 million, mainly because of the March 4, 2026 acquisition of Quantum X Labs Ltd. in Israel, which added $14.3 million of goodwill and $1.2 million of in-process R&D.
Cash and cash equivalents were $1.8 million as of March 31, 2026, against bank loans of about $1.4 million and an accumulated deficit of $46.7 million. Management explicitly states that declining revenues, continued losses and reliance on external financing raise substantial doubt about the company’s ability to continue as a going concern, even after raising $1.4 million in a March 2026 private placement and completing its Nasdaq uplisting and earlier 2025 financings.
Quantum X Labs Inc. reported unaudited results for the quarter ended March 31, 2026, showing a small business focused on quantum technology and digital advertising that is still losing money. Revenue from continuing operations was $353 thousand, down from $529 thousand a year earlier, while net loss attributable to shareholders narrowed to $605 thousand from $3.7 million. Total assets rose to $27.7 million, mainly because of the March 4, 2026 acquisition of Quantum X Labs Ltd. in Israel, which added $14.3 million of goodwill and $1.2 million of in-process R&D.
Cash and cash equivalents were $1.8 million as of March 31, 2026, against bank loans of about $1.4 million and an accumulated deficit of $46.7 million. Management explicitly states that declining revenues, continued losses and reliance on external financing raise substantial doubt about the company’s ability to continue as a going concern, even after raising $1.4 million in a March 2026 private placement and completing its Nasdaq uplisting and earlier 2025 financings.
Quantum X Labs Inc. is providing audited 2025 financials and pro forma data for its March 4, 2026 acquisition of Quantum X Labs Ltd. in Israel. The acquired business generated no revenue in 2025, recorded a $325 thousand net loss and faces a going concern uncertainty due to ongoing losses and financing needs. Pro forma 2025 results combine $1.57 million of revenue with a $21.14 million net loss. The acquisition reflects a total purchase cost of $15.89 million, including a $10.67 million share and warrant consideration and a $5.22 million earn-out, creating $20.72 million of goodwill and $3.65 million of intangible assets on the combined balance sheet.
Quantum X Labs Inc. is providing audited 2025 financials and pro forma data for its March 4, 2026 acquisition of Quantum X Labs Ltd. in Israel. The acquired business generated no revenue in 2025, recorded a $325 thousand net loss and faces a going concern uncertainty due to ongoing losses and financing needs. Pro forma 2025 results combine $1.57 million of revenue with a $21.14 million net loss. The acquisition reflects a total purchase cost of $15.89 million, including a $10.67 million share and warrant consideration and a $5.22 million earn-out, creating $20.72 million of goodwill and $3.65 million of intangible assets on the combined balance sheet.
Quantum X Labs Inc., formerly Viewbix Inc., has changed its corporate name and Nasdaq trading symbol. Effective April 30, 2026, the company’s name became Quantum X Labs Inc. and its ticker switched from VBIX to QXL, with related charter and bylaw amendments limited to the new name.
The company states that the name change and symbol change do not affect security holders’ rights, and existing stock certificates remain valid. A concurrent press release highlights a broader rebranding toward quantum computing, quantum error correction, simulations, and quantum sensing, while maintaining its legacy digital advertising and AI-driven software businesses.
Viewbix Inc. is rebranding as Quantum X Labs Inc. and shifting its market identity toward quantum technologies while keeping its existing digital advertising operations. The company’s Nasdaq ticker will change from VBIX to QXL, with trading under the new symbol beginning on April 30, 2026.
The filing states that shareholder rights are unchanged, the CUSIP number remains the same, and existing stock certificates stay valid, with new certificates reflecting the Quantum X Labs name issued over time. Through wholly owned subsidiary Quantum X Labs Ltd. and several partially owned portfolio companies, the group is focusing on quantum computing, quantum error correction, sensing, navigation, atomic clocks, cybersecurity, and life-science applications, alongside its legacy Gix Media and Metagramm software businesses.
Viewbix Inc. files a registration statement to permit the resale of up to 1,472,000 shares of common stock, consisting of 800,000 shares issued in a private placement, 640,000 shares issuable on exercise of Common Warrants, and 32,000 shares issuable on exercise of Advisor Warrants. The resale proceeds will go to the selling stockholders; the company will receive proceeds only if warrants are exercised for cash. The prospectus states shares outstanding were 13,336,392 as of April 1, 2026. The filing also discloses the March 4, 2026 acquisition of Quantum (Quantum became a wholly-owned subsidiary) and potential additional issuance of up to 12,702,847 Earn-Out Securities upon achievement of specified milestones.